Murai Taro, Kasai Yuki, Eguchi Yuta, Takano Seiya, Kita Nozomi, Torii Akira, Takaoka Taiki, Tomita Natsuo, Shibamoto Yuta, Hiwatashi Akio
Department of Radiation Oncology, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura 247-8533, Kanagawa, Japan.
Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-ku, Nagoya 467-8601, Aichi, Japan.
Cancers (Basel). 2024 Sep 28;16(19):3327. doi: 10.3390/cancers16193327.
The objective was to explore dosimetric predictors of brain necrosis (BN) in fractionated stereotactic radiotherapy (SRT).
After excluding collinearities carefully, multivariate logistic models were developed for comprehensive analyses of dosimetric predictors in patients who received first-line fractionated SRT for brain metastases (BMs). The normal brain volume receiving an xx Gy biological dose in 2 Gy fractions (VxxEQD2) was calculated from the retrieved dose-volume parameters.
Thirty Gy/3 fractions (fr) SRT was delivered to 34 patients with 75 BMs (median target volume, 3.2 cc), 35 Gy/5 fr to 30 patients with 57 BMs (6.4 cc), 37.5 Gy/5 fr to 28 patients with 47 BMs (20.2 cc), and 40 Gy/10 fr to 20 patients with 37 BMs (24.3 cc), according to protocols, depending on the total target volume ( < 0.001). After excluding the three-fraction groups, the incidence of symptomatic BN was significantly higher in patients with a larger V50EQD2 (adjusted odds ratio: 1.07, < 0.02), V55EQD2 (1.08, < 0.01), or V60EQD2 (1.09, < 0.01) in the remaining five- and ten-fraction groups. The incidence of BN was also significantly higher in cases with V55EQD2 > 30 cc or V60EQD2 > 20 cc ( < 0.05). These doses correspond to 28 or 30 Gy/5 fr and 37 or 40 Gy/10 fr, respectively.
In five- or ten-fraction SRT, larger V55EQD2 or V60EQD2 are BN risk predictors. These biologically high doses may affect BN incidence. Thus, the planning target volume margin should be minimized as much as possible.
目的是探讨分次立体定向放射治疗(SRT)中脑坏死(BN)的剂量学预测因素。
在仔细排除共线性后,建立多变量逻辑模型,对接受一线分次SRT治疗脑转移瘤(BMs)患者的剂量学预测因素进行综合分析。根据检索到的剂量体积参数计算接受2 Gy分次照射、生物剂量为xx Gy的正常脑体积(VxxEQD2)。
根据方案,依据总靶体积(<0.001),对34例有75个BMs的患者给予30 Gy/3分次SRT(中位靶体积,3.2 cc),对30例有57个BMs的患者给予35 Gy/5分次SRT(6.4 cc),对28例有47个BMs的患者给予37.5 Gy/5分次SRT(20.2 cc),对20例有37个BMs的患者给予40 Gy/10分次SRT(24.3 cc)。排除三分次组后,在其余的五分次和十分次组中,V50EQD2较大(调整优势比:1.07,<0.02)、V55EQD2较大(1.08,<0.01)或V60EQD2较大(1.09,<0.01)的患者中,有症状BN的发生率显著更高。V55EQD2>30 cc或V60EQD2>20 cc的病例中BN的发生率也显著更高(<0.05)。这些剂量分别对应于28或30 Gy/5分次以及37或40 Gy/10分次。
在五分次或十分次SRT中,较大的V55EQD2或V60EQD2是BN的风险预测因素。这些生物高剂量可能影响BN的发生率。因此,计划靶体积边缘应尽可能最小化。